Benzinga

Benzinga

Benzinga

viernes, agosto 21

Cue Biopharma Inc

CUENASDAQ
Trade with Public
Trade with Public
$24.61
-1.67-6.35%
al cierre: Aug 20, 5:00 PM EST
$26.60
1.998.09%
After hour: 9:24 AM EST
Ganancias: Los beneficios de Q2 2026 se publicaron el vie ago 14th, después del cierre del mercado
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Cue Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cue Biopharma (CUE).

Price Target Range — 6 Quarters

Analyst Consensus — 7 Analysts

2S.Buy
5Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$4Upside to Avg. PT-83.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2025LUCID CAPITAL MARKETSDev Prasad InitiateBuy$4
Apr 2, 2025Citizens Capital MarketsReni BenjaminMaintainedMarket Outperform$2
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $4

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Target of $4.
Benzinga Newsdesk

PRO
Citizens Capital Markets Reiterates Market Outperform on Cue Biopharma, Maintains $2 Price Target

Citizens Capital Markets analyst Reni Benjamin reiterates Cue Biopharma (NASDAQ:CUE) with a Market Outperform and maintains $2 price target.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Cue Biopharma, Lowers Price Target to $4

Stifel analyst Stephen Willey maintains Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $8 to $4.
Benzinga Newsdesk

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma, Inc. (NASDAQ: CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.
Zacks

PRO
JMP Securities Maintains Market Outperform on Cue Biopharma, Lowers Price Target to $2

JMP Securities analyst Reni Benjamin maintains Cue Biopharma (NASDAQ:CUE) with a Market Outperform and lowers the price target from $15 to $2.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Cue Biopharma, Lowers Price Target to $3

Piper Sandler analyst Edward Tenthoff maintains Cue Biopharma (NASDAQ:CUE) with a Overweight and lowers the price target from $8 to $3.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved